cbdMD Appoints Wade Brown Chief Marketing Officer
Rhea-AI Summary
cbdMD (NYSE American: YCBD) named Wade Brown as Chief Marketing Officer, elevating him to lead marketing and commercial growth across cbdMD, Paw CBD, Oasis, Bluebird Botanicals, and future brands.
According to cbdMD, recent revenue grew 19% year-over-year and 12% sequentially, supported by core brands and Bluebird integration.
AI-generated analysis. Not financial advice.
Positive
- Recent revenue growth of 19% year-over-year and 12% sequentially
- Experienced CMO appointed to lead multi-brand marketing and growth
- Expanded focus on DTC, Amazon, retail, wholesale, and CRM channels
- Supports strategy to build a broader multi-brand wellness platform
Negative
- None.
News Market Reaction – YCBD
On the day this news was published, YCBD declined 0.30%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Peers on Argus
Momentum data show mixed sector moves: peers like IMCC and CPHI were up as much as 14.37% and 7.59%, while SHPH and RDHL were down around 6–7%. With 2 peers up and 2 down, sector dynamics rather than a unified trend dominated.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 14 | Earnings and acquisition | Positive | -5.3% | Reported 19% YoY and 12% sequential revenue growth with Bluebird integration. |
| May 12 | Earnings call notice | Neutral | -3.0% | Announced conference call to discuss Q2 results and business progress. |
| May 05 | Board changes (peer) | Neutral | -0.7% | Hawkeye Systems expanded its board and outlined strategic shift. |
| Apr 01 | Clinical channel launch | Positive | -3.5% | Launched clinical healthcare channel for hemp-derived CBD in Medicare models. |
| Feb 17 | Earnings and financing | Positive | -6.8% | Reported Q1 revenue growth, Series C financing, and Bluebird acquisition close. |
Recent cbdMD announcements, including revenue growth and strategic initiatives, were followed by negative 24-hour price reactions, suggesting cautious sentiment toward company news pre-dating this appointment.
Over the past several months, cbdMD reported sequential revenue increases, net sales of $5.0M–$5.6M, improved working capital of $5.4M, and progress integrating the Bluebird Botanicals acquisition. It also launched a clinical healthcare channel tied to Medicare value-based models and extended its facilities lease to reduce rent. Despite these operational steps, shares reacted negatively after each prior announcement, indicating investors focused on ongoing losses and going-concern risks ahead of this CMO appointment.
Regulatory & Risk Context
Market Pulse Summary
This announcement highlights cbdMD’s effort to professionalize and scale its multi-brand wellness platform by elevating an experienced operator to CMO after reporting 19% year-over-year and 12% sequential revenue growth. It follows months of Bluebird Botanicals integration, clinical-channel development tied to Medicare models, and facilities and compensation restructuring. Investors may watch how marketing execution affects revenue mix, progress toward profitability, and the company’s ability to address going-concern risks disclosed in recent regulatory filings.
Key Terms
cannabinoid medical
crm technical
omnichannel technical
medicare regulatory
AI-generated analysis. Not financial advice.
Veteran consumer-wellness growth operator to lead multi-brand expansion across DTC, Amazon, retail, and new categories
Brown joined cbdMD in March 2025 and has been central to stabilizing the Company's brand portfolio and supporting its acquisition of Bluebird Botanicals. Most recently, cbdMD reported
Prior to joining cbdMD, Brown held senior marketing and growth leadership roles across a range of consumer brands, including NatureWise, Vanity Planet, Inc Authority (prior to its acquisition by LegalZoom), First Tactical, Noble Outfitters, and Kevin's Naturals. His experience spans dietary supplements, beauty, online services, and omnichannel CPG, with deep expertise in ecommerce, Amazon, performance marketing, and brand portfolio growth.
"Wade has been instrumental in stabilizing our brands and bringing discipline to our marketing," said Ronan Kennedy, Chief Executive Officer and Chief Financial Officer of cbdMD. "He's an operator, not just a marketer. Wade understands DTC, Amazon, retail, creative, CRM, and customer acquisition. As we sharpen our focus on health and wellness, his experience scaling consumer brands within and beyond hemp will be key to driving our next phase of growth."
As Chief Marketing Officer, Brown will report to the CEO and lead marketing and commercial growth across cbdMD's portfolio, including cbdMD, Paw CBD, Oasis, Bluebird Botanicals, and future brands. Spanning brand strategy, DTC and marketplace execution, retail and wholesale support, creative, CRM and retention, and product-launch strategy. His appointment supports cbdMD's evolution into a broader multi-brand wellness platform across CBD, pet, botanical, and functional wellness and adjacent consumer health categories, including the Company's clinical healthcare channel for hemp-derived cannabinoid products in value-based Medicare models.
"cbdMD has built real trust and a loyal customer base," said Brown. "CBD and hemp wellness remain a strong foundation, but the bigger opportunity is a multi-brand consumer wellness platform. Built on clear positioning, disciplined execution, and modern growth systems across DTC, Amazon, retail, and CRM. My focus is building that operating system and creating lasting value for our customers and shareholders."
About cbdMD, Inc.
cbdMD, Inc. (NYSE American: YCBD) is one of the leading and most highly trusted and recognized cannabidiol (CBD) brands with a comprehensive line of U.S. produced THC-free1 CBD products and an array of Farm Bill compliant Delta 9 products. To learn more about cbdMD as well as our other brands, please visit www.cbdmd.com, www.pawcbd.com, www.ATRxLabs.com, www.bluebirdbotanicals.com, or www.herbaloasis.com, follow cbdMD on Instagram and Facebook, or visit one of the thousands of retail outlets that carry cbdMD's products.
1THC-free is defined as below the level of detection using validated scientific analytical methods.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Words such as "expect," "intend," "will," "anticipate," "believe," "position," "look to," and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding the Company's strategy, expansion beyond hemp into broader health and wellness categories, anticipated growth, the expected contributions of its leadership team, and its clinical healthcare and other initiatives. Forward-looking statements are based on management's current expectations and assumptions and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially, including those described in the Company's filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement except as required by law.
Contacts
cbdMD, Inc.
Ronan Kennedy
Chief Executive Officer and Chief Financial Officer
IR@cbdmd.com
(704) 445-3064
View original content to download multimedia:https://www.prnewswire.com/news-releases/cbdmd-appoints-wade-brown-chief-marketing-officer-302801832.html
SOURCE cbdMD, Inc.